Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy
Sign Up to like & getrecommendations! Published in 2025 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2024.2132
Abstract: Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP,… read more here.
Keywords: effectiveness hypocalcemia; malignancy; calcium levels; hypocalcemia ... See more keywords